# A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

> **NCT01121575** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** PF-02341066
- **DRUG:** PF-00299804
- **DRUG:** PF-02341066
- **DRUG:** PF-00299804

## Key facts

- **NCT ID:** NCT01121575
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121575, "A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01121575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*